Corient Private Wealth LLC raised its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 0.2% during the fourth quarter, HoldingsChannel reports. The fund owned 632,803 shares of the biopharmaceutical company’s stock after acquiring an additional 1,163 shares during the quarter. Corient Private Wealth LLC’s holdings in Gilead Sciences were worth $58,452,000 as of its most recent SEC filing.
Other hedge funds also recently added to or reduced their stakes in the company. HHM Wealth Advisors LLC lifted its position in shares of Gilead Sciences by 118.5% during the fourth quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 154 shares during the last quarter. YANKCOM Partnership acquired a new stake in Gilead Sciences during the fourth quarter valued at approximately $28,000. Decker Retirement Planning Inc. bought a new position in Gilead Sciences during the 4th quarter worth approximately $29,000. Crews Bank & Trust acquired a new position in shares of Gilead Sciences in the 4th quarter worth approximately $31,000. Finally, Stephens Consulting LLC increased its holdings in shares of Gilead Sciences by 325.0% in the 4th quarter. Stephens Consulting LLC now owns 340 shares of the biopharmaceutical company’s stock valued at $31,000 after acquiring an additional 260 shares during the last quarter. 83.67% of the stock is owned by institutional investors and hedge funds.
Insider Buying and Selling at Gilead Sciences
In related news, CFO Andrew D. Dickinson sold 17,929 shares of Gilead Sciences stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $118.17, for a total value of $2,118,669.93. Following the transaction, the chief financial officer now owns 169,061 shares of the company’s stock, valued at approximately $19,977,938.37. This trade represents a 9.59 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Over the last 90 days, insiders have sold 302,785 shares of company stock valued at $30,503,250. Corporate insiders own 0.16% of the company’s stock.
Analyst Ratings Changes
Read Our Latest Research Report on GILD
Gilead Sciences Stock Down 1.7 %
GILD opened at $111.44 on Monday. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.20 and a current ratio of 1.50. The company has a market capitalization of $138.78 billion, a PE ratio of 301.19, a P/E/G ratio of 0.71 and a beta of 0.21. The stock’s fifty day moving average is $101.82 and its 200-day moving average is $92.92. Gilead Sciences, Inc. has a one year low of $62.07 and a one year high of $119.96.
Gilead Sciences (NASDAQ:GILD – Get Free Report) last issued its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 EPS for the quarter, topping the consensus estimate of $1.67 by $0.23. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. On average, equities analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.
Gilead Sciences Increases Dividend
The firm also recently declared a quarterly dividend, which will be paid on Friday, March 28th. Shareholders of record on Friday, March 14th will be given a $0.79 dividend. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.77. The ex-dividend date is Friday, March 14th. This represents a $3.16 annualized dividend and a yield of 2.84%. Gilead Sciences’s payout ratio is 854.05%.
About Gilead Sciences
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
Featured Stories
- Five stocks we like better than Gilead Sciences
- The 3 Best Blue-Chip Stocks to Buy Now
- How to Build the Ultimate Everything ETF Portfolio
- Manufacturing Stocks Investing
- Dutch Bros or Starbucks: Which Coffee Stock Has More Growth?
- What Does a Stock Split Mean?
- 3 Stocks With High ROE and Market-Beating Growth Potential
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD – Free Report).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.